Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Shandong Weigao Group Medical Polymer Co Cash Ratio?
Shandong Weigao Group Medical Polymer CoSHWGF 57 Cash Ratio is 1.73 as of Dec. 2025, which is 28% above its 10-year median of 1.35. GuruFocus rates SHWGF with a GF Scoreâ„¢ of 57/100 and a GF Valueâ„¢ of $0.80 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 840 Medical Devices & Instruments companies, Shandong Weigao Group Medical Polymer Co ranks better than 64.29% on this metric.
Shandong Weigao Group Medical Polymer Co has a Cash Ratio of 1.73. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
SHWGF's Cash Ratio is ranked better than 64.29% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 0.975
vs SHWGF: 1.73
Shandong Weigao Group Medical Polymer Co (OTCPK:SHWGF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Shandong Weigao Group Medical Polymer Co Cash Ratio Related Terms
Shandong Weigao Group Medical Polymer Co Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Group Medical Polymer Co Cash Ratio Chart
Shandong Weigao Group Medical Polymer Co Annual Data
For the Medical Instruments & Supplies subindustry, Shandong Weigao Group Medical Polymer Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Weigao Group Medical Polymer Co Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shandong Weigao Group Medical Polymer Co's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Shandong Weigao Group Medical Polymer Co's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Group Medical Polymer Co (SHWGF) has a Cash Ratio of 1.73 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Shandong Weigao Group Medical Polymer Co and its competitors. This is 28% above median its historical median of 1.35. Over the past decade, Shandong Weigao Group Medical Polymer Co's Cash Ratio has ranged from 0.97 to 1.73. According to the industry distribution chart, Shandong Weigao Group Medical Polymer Co ranks #300 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 35.7%.
Is Shandong Weigao Group Medical Polymer Co's Cash Ratio too high?
Shandong Weigao Group Medical Polymer Co's current Cash Ratio of 1.73 is 28% above median its 10-year median of 1.35. Over the past 10 years, this metric has ranged from a low of 0.97 to a high of 1.73. The Medical Devices & Instruments industry median Cash Ratio is 0.98. Shandong Weigao Group Medical Polymer Co's value of 1.73 is 77.4% above this industry median. Based on the distribution chart, Shandong Weigao Group Medical Polymer Co ranks #300 out of 840 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shandong Weigao Group Medical Polymer Co has a GF Scoreâ„¢ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Weigao Group Medical Polymer Co's Cash Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Shandong Weigao Group Medical Polymer Co ranks #300 out of 840 companies for Cash Ratio. This puts Shandong Weigao Group Medical Polymer Co in the upper half of its industry. The industry median Cash Ratio is 0.98. Shandong Weigao Group Medical Polymer Co's value of 1.73 is 77.4% above this benchmark. Historically, Shandong Weigao Group Medical Polymer Co's own Cash Ratio has ranged from 0.97 to 1.73 over the past decade. While the company's 10-year median is 1.35 vs. the industry median of 0.98, Shandong Weigao Group Medical Polymer Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.98, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Weigao Group Medical Polymer Co's current Cash Ratio of 1.73 is 77.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Shandong Weigao Group Medical Polymer Co and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Weigao Group Medical Polymer Co's current Cash Ratio is 1.73, which is 28% above median its own 10-year median of 1.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Weigao Group Medical Polymer Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Weigao Group Medical Polymer Co (SHWGF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.80, compared to a current price of $0.43 — trading 45.7% below its estimated fair value. The current Cash Ratio is 1.73, which is 28% above median its 10-year median of 1.35 and 77.4% above the Medical Devices & Instruments industry median of 0.98. Shandong Weigao Group Medical Polymer Co's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Shandong Weigao Group Medical Polymer Co (SHWGF), the current Cash Ratio is 1.73 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Weigao Group Medical Polymer Co (SHWGF) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Weigao Group Medical Polymer Co stock appears to be undervalued.
The current stock price of $0.43 is trading 45.7% below its estimated GF Value™ of $0.80.
GuruFocus considers Shandong Weigao Group Medical Polymer Co to be Significantly Undervalued.
Key valuation signals for SHWGF:
Cash Ratio: 1.73 (28% above median its 10-year median of 1.35)
GF Value™: $0.80 vs. price of $0.43 (45.7% below fair value)
Industry Position: 77.4% above the Medical Devices & Instruments median (#300 of 840)
No single metric tells the full story. See the SHWGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Weigao Group Medical Polymer Co Business Description
Shandong Weigao Group Medical Polymer Co Ltd functions in the healthcare sector in China. Its business mainly involves the research and development, production, and sale of single-use medical device products. The company's segments include Medical device products, Orthopaedic products, Interventional products, Pharma packaging products, Blood management products, and others. The company's products comprise consumables including infusion sets, syringes, medical needles, blood bags, prefilled syringes, wound management, blood sampling products; orthopedic materials, and blood purification consumables and equipment. The company operates in the People's Republic of China, the United States, Europe, the Middle East, and Africa, Asia, and others.
57GF Score
Get the complete analysis for SHWGF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHWGF has been successfully added to your 
